Literature DB >> 14671091

Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure.

Rose Tsui1, Belinda L Herring, Jason D Barbour, Robert M Grant, Peter Bacchetti, Alex Kral, Brian R Edlin, Eric L Delwart.   

Abstract

Evidence for human immunodeficiency virus type 1 (HIV-1) superinfection was sought among 37 HIV-1-positive street-recruited active injection drug users (IDUs) from the San Francisco Bay area. HIV-1 sequences from pairs of samples collected 1 to 12 years apart, spanning a total of 215 years of exposure, were generated at p17 gag, the V3-V5 region of env, and/or the first exon of tat and phylogenetically analyzed. No evidence of HIV-1 superinfection was detected in which a highly divergent HIV-1 variant emerged at a frequency >20% of the serum viral quasispecies. Based on the reported risk behavior of the IDUs and the HIV-1 incidence in uninfected subjects in the same cohort, a total of 3.4 new infections would have been expected if existing infection conferred no protection from superinfection. Adjusted for risk behaviors, the estimated relative risk of superinfection compared with initial infection was therefore 0.0 (95% confidence interval, 0.00, 0.79; P = 0.02), indicating that existing infection conferred a statistically significant level of protection against superinfection with an HIV-1 strain of the same subtype, which was between 21 and 100%.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14671091      PMCID: PMC303392          DOI: 10.1128/jvi.78.1.94-103.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  88 in total

1.  HIV-1 gp120 sequences from a doubly infected drug user.

Authors:  M Sala; E Pelletier; S Wain-Hobson
Journal:  AIDS Res Hum Retroviruses       Date:  1995-05       Impact factor: 2.205

2.  Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group.

Authors:  R S Diaz; E C Sabino; A Mayer; J W Mosley; M P Busch
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays.

Authors:  E L Delwart; H W Sheppard; B D Walker; J Goudsmit; J I Mullins
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

4.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.

Authors:  J D Thompson; D G Higgins; T J Gibson
Journal:  Nucleic Acids Res       Date:  1994-11-11       Impact factor: 16.971

5.  Functional characterization of human immunodeficiency virus type 1 nef genes in patients with divergent rates of disease progression.

Authors:  N L Michael; G Chang; L A d'Arcy; C J Tseng; D L Birx; H W Sheppard
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans.

Authors:  A W Artenstein; T C VanCott; J R Mascola; J K Carr; P A Hegerich; J Gaywee; E Sanders-Buell; M L Robb; D E Dayhoff; S Thitivichianlert
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

7.  Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users.

Authors:  Artur Ramos; Dale J Hu; Lily Nguyen; Kim-Oanh Phan; Suphak Vanichseni; Nattawan Promadej; Kachit Choopanya; Margaret Callahan; Nancy L Young; Janet McNicholl; Timothy D Mastro; Thomas M Folks; Shambavi Subbarao
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

8.  Reactivation of human immunodeficiency virus type 2 in macaques after simian immunodeficiency virus SIVmac superinfection.

Authors:  H Petry; U Dittmer; C Stahl-Hennig; C Coulibaly; B Makoschey; D Fuchs; H Wachter; T Tolle; C Morys-Wortmann; F J Kaup
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

9.  Evidence for coinfection by multiple strains of human immunodeficiency virus type 1 subtype B in an acute seroconvertor.

Authors:  T Zhu; N Wang; A Carr; S Wolinsky; D D Ho
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

10.  Long-term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine.

Authors:  P Putkonen; L Walther; Y J Zhang; S L Li; C Nilsson; J Albert; P Biberfeld; R Thorstensson; G Biberfeld
Journal:  Nat Med       Date:  1995-09       Impact factor: 53.440

View more
  25 in total

Review 1.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

2.  Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.

Authors:  Steven G Deeks; Becky Schweighardt; Terri Wrin; Justin Galovich; Rebecca Hoh; Elizabeth Sinclair; Peter Hunt; Joseph M McCune; Jeffrey N Martin; Christos J Petropoulos; Frederick M Hecht
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 3.  Immunological and virological characteristics of human immunodeficiency virus type 1 superinfection: implications in vaccine design.

Authors:  Yang Gao; Wen Tian; Xiaoxu Han; Feng Gao
Journal:  Front Med       Date:  2017-11-23       Impact factor: 4.592

4.  Timing and source of subtype-C HIV-1 superinfection in the newly infected partner of Zambian couples with disparate viruses.

Authors:  Colleen S Kraft; Debby Basu; Paulina A Hawkins; Peter T Hraber; Elwyn Chomba; Joseph Mulenga; William Kilembe; Naw H Khu; Cynthia A Derdeyn; Susan A Allen; Olivier Manigart; Eric Hunter
Journal:  Retrovirology       Date:  2012-03-20       Impact factor: 4.602

5.  A Multi-Vector, Multi-Envelope HIV-1 Vaccine.

Authors:  Julia L Hurwitz; Xiaoyan Zhan; Scott A Brown; Mattia Bonsignori; John Stambas; Timothy D Lockey; Bart Jones; Sherri Surman; Robert Sealy; Pam Freiden; Kristen Branum; Karen S Slobod
Journal:  J Pediatr Pharmacol Ther       Date:  2007-04

Review 6.  Primary human immunodeficiency virus type 1 infection.

Authors:  Malini Soogoor; Eric S Daar
Journal:  Curr HIV/AIDS Rep       Date:  2005-06       Impact factor: 5.071

7.  Relative replication capacity of phenotypic SIV variants during primary infections differs with route of inoculation.

Authors:  Tasha Biesinger; Robert White; Monica T Yu Kimata; Brenda K Wilson; Jonathan S Allan; Jason T Kimata
Journal:  Retrovirology       Date:  2010-10-13       Impact factor: 4.602

8.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

9.  HIV-1 superinfection in the antiretroviral therapy era: are seroconcordant sexual partners at risk?

Authors:  Mary S Campbell; Geoffrey S Gottlieb; Stephen E Hawes; David C Nickle; Kim G Wong; Wenjie Deng; Thomas M Lampinen; Nancy B Kiviat; James I Mullins
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

10.  Multiple-infection and recombination in HIV-1 within a longitudinal cohort of women.

Authors:  Alan R Templeton; Melissa G Kramer; Joseph Jarvis; Jeanne Kowalski; Stephen Gange; Michael F Schneider; Qiujia Shao; Guang Wen Zhang; Mei-Fen Yeh; Hua-Ling Tsai; Hong Zhang; Richard B Markham
Journal:  Retrovirology       Date:  2009-06-03       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.